Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine
Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children with Debilitating, Lifelong Hereditary Disease Ultragenyx…